<DOC>
	<DOCNO>NCT00143091</DOCNO>
	<brief_summary>A six week , fix dose , double-blind , double-dummy , placebo , active control , multicentre trial evaluate safety efficacy CP-316,311 outpatient major depressive disorder .</brief_summary>
	<brief_title>Multicentre Trial Evaluate Safety Efficacy CP-316,311 Major Depressive Disorder</brief_title>
	<detailed_description>This study terminate March 17th , 2006 . The result primary analysis interim show CP-316,311 group significantly different placebo primary endpoint therefore data monitor committee recommend termination trial . The decision terminate trial base safety concern .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>Outpatients DSMIV major depressive disorder Women child bear potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Major Depressive Disorder , Recurrent</keyword>
</DOC>